Grail's Galleri, a blood test designed to screen for multiple cancers, is moving closer to FDA approval. Healthcare Dive asked five doctors what encourages and concerns them most about the test. Their responses, published in a new article, capture the cautious optimism surrounding the technology.
The doctors agree that the test has potential to improve early detection, especially for cancers that are hard to find. They also agree that limitations need to be addressed before the test can be widely used. However, they differ in how much weight they give to those limitations, with some more enthusiastic than others.
The article highlights that Galleri is closely watched by the medical community. As it advances through the regulatory process, the doctors' perspectives underscore the balance between hope and evidence that will shape its future.